Phase 3 N=1 Lucentis (Ranibizumab) for Eales' Disease
Eales' Disease
Primary: Change in OCT Thickness. — 269; 262 um
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=49 EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection
Macular Degeneration · Wet Macular Degeneration
Primary: Anatomic Response
Phase 1 N=6 Efalizumab to Treat Uveitis
Uveitis · Macular Edema
Primary: Number of Participants With Systemic Toxicities, Adverse Events, or Infections — 6 Participants
Phase 2 N=15 Eplerenone for Central Serous Chorioretinopathy
Central Serous Chorioretinopathy
Primary: Complete Resolution of Subretinal Fluid — 0 participants
N/A N=12 Multimodal Analysis and Electroretinogram in VKH From Acute Onset - Part I
Uveomeningoencephalitic Syndrome · Inflammation · Choroid Disease
Primary: Median Values of ERG Scotopic Parameters at 12-month — 201; 210; 508; 92 microvolts — p=<0.001
Phase 2 N=7 Lucentis for Inflammatory Macular Edema Trial
Uveitis · Cytoid Macular Edema
Primary: The Mean Change at 3 Months in BSCVA From Baseline — 13 letters
N/A N=5 Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema
Uveitis · Cystoid Macular Edema
Primary: Improvement in VA ETDRS >/= 15 Letters — 1 participants
N/A N=18 Eplerenone for the Treatment of Central Serous Chorioretinopathy
Central Serous Chorioretinopathy
Primary: Mean Change in Maximal Subretinal Fluid Height Based on Spectral Domain Optical Coherence Tomography (OCT) Measurement. — 139.3; 135.9; 51.8; 172.3 microns
Phase 4 N=70 Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection
Corneal Endothelial Dystrophy · Corneal Edema
Primary: Immunologic Rejection — 0 Participants
Phase 2 N=52 ESBA1008 Microvolume Study
Exudative Age-Related Macular Degeneration
Primary: Percentage of Responders Based on CSFT and BCVA Outcomes at Day 14 and Day 28 — 70; 60; 80; 60 percentage of responders
N/A N=45 Dyslipidemia and Diabetic Retinopathy
Diabetic Retinopathy · Dyslipidemia
Primary: Increase in Acid Sphingomyelinase (ASM) Expression and Activity in Bone Marrow-derived Endothelial Progenitor Cells (EPCs) — 0.2; 0.5 nM/hr
Phase 3 N=466 Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema
Diabetic Macular Edema
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation…
Phase 2 N=131 Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD)
Age Related Macular Degeneration
Primary: Production of Anti-Retinal Pigment Epithelium (RPE) or Anti-retinal Antibody Formation in Neovascular ("Wet") Age-related Macular Degeneration Patients Compared to…
Phase 3 N=1,009 Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye
Neovascular Age-Related Macular Degeneration
Primary: Change From Baseline in BCVA Measured by the ETDRS Letter Score at Week 48 — 7.03; 6.06; 5.89 scores on a scale — p=0.0009
Phase 2 N=221 DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact
Diabetic Macular Edema
Primary: Change in BCVA From Baseline to Week 24 - Last Observation Carried Forward (LOCF) — 2.5; 8.6; 11.4; 8.5 letters correctly read
N/A N=21 Early Experience With Descemet's Stripping Automated Endothelial Keratoplasty
Corneal Edema Secondary to Corneal Endothelial Dystrophy
Primary: Best Spectacle Corrected Visual Acuity (BSCVA) — 1; 3; 7; 9 Participants
Phase 2 N=42 Topical Steroid Treatment for Eosinophilic Esophagitis
Eosinophilic Esophagitis
Primary: Number of Participants With Complete Response to Dysphagia — 9; 6 participants — p=0.74
Phase 2 N=30 Aflibercept for Macular Oedema With Underlying Retinitis Pigmentosa (AMOUR) Study
Macular Oedema · Retinitis Pigmentosa
Primary: Mean Central Macular Thickness (CMT) on Spectral Domain OCT (SDOCT) at 12 Months — 413.4 Microns
Phase 2 N=6 Apremilast for Erythema Multiforme
Erythema Multiforme
Primary: Erythema Multiforme Flares on Medication — 1.7 Number of flares
Phase 2 N=3 A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab
Von Hippel-Lindau Syndrome
Primary: Tabulation of Adverse Events — 13 adverse events
Phase 2 N=183 Efficacy Study of Ecabet Ophthalmic Solution in Dry Eye Disease
Dry Eye Disease
Primary: Mean Change From Baseline in Lacrimation Assessed by Schirmer's Test — 3.02; 2.15; 2.35; 1.35 mm
Phase 3 N=118 Phase III Study in Refractory Behcet's Disease
Behcet Disease
Primary: Rate of Recurrent Ocular Exacerbations in the Study Eye During 24 Weeks by Treatment — 7.7; 11.5; 7.7 Ocular Exacerbations
Phase 1 N=6 Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy
Dense Deposit Disease · Membranoproliferative Glomerulonephritis
Primary: Number of Patients With Change in Proteinuria or Serum Creatinine Over Treatment Period — 5 Participants
Phase 2 N=18 Crizanlizumab for Treatment of Retinal Vasculopathy With Cerebral Leukoencephalopathy (RVCL)
RVCL - Retinal Vasculopathy Cerebral Leukoencephalopathy
Primary: Change in the Percentage of White Matter Hyperintensity (WMH) Lesion Volume on FLAIR MRI in RVCL Patients — 31.3 Percent (%)
Phase 4 N=31 Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO
Retinal Vein Occlusion · Diabetic Macular Edema · Branch Retinal Vein Occlusion
Primary: Change in Panretinal Leakage Index at Month 12 From Baseline — -3.14 percentage of region of interest in UWFA
Phase 2 N=20 Diabetic Macular Edema Treated With Ozurdex (DMEO)
Diabetic Macular Edema
Primary: Correlation Between Change in Level of Propermeability Factors With Change in Edema After Treatment With a Dexamethasone Implant or Anti-VEGF Agent — 0.47; 0.059; 0.45…
Phase 3 N=160 Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis
Uveitis · Uveitis, Posterior · Uveitis, Anterior
Primary: Number of Subjects Demonstrating ≥ 15 Letter Improvement From Baseline in Best Corrected Visual Acuity at 24 Weeks — 45; 10 Participants — p=<0.001
Phase 2 N=8 Gevokizumab for Active Scleritis
Scleritis
Primary: Number of Participants With at Least a 2-step Reduction or Reduction to Grade 0 in Scleral Inflammation in the Study Eye (or Eyes), According to the National Eye…
Phase 4 N=62 A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease
Thyroid Eye Disease · Chronic (Inactive) Thyroid Eye Disease
Primary: Change From Baseline in Proptosis of Study Eye at Week 24 — -2.41; -0.92 Millimieter (mm) — p=0.0004
Phase 2 N=30 Prevention of Macular Edema In Patients With Diabetic Retinopathy Undergoing Cataract Surgery
Diabetic Retinopathy
Primary: Number of Participants With Ocular and Non-Ocular Adverse Events — 11; 10; 5; 3 Participants